An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)

BACKGROUND: Shortening duration of peginterferon-based HCV treatment reduces associated burden for patients. Primary objectives of this study were to assess the efficacy against the minimally acceptable response rate 12 weeks post-treatment (SVR12) and safety of simeprevir plus PR in treatment-naïve...

Descripción completa

Detalles Bibliográficos
Autores principales: Asselah, Tarik, Moreno, Christophe, Sarrazin, Christoph, Gschwantler, Michael, Foster, Graham R., Craxí, Antonio, Buggisch, Peter, Ryan, Robert, Lenz, Oliver, Scott, Jane, Van Dooren, Gino, Lonjon-Domanec, Isabelle, Schlag, Michael, Buti, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948848/
https://www.ncbi.nlm.nih.gov/pubmed/27428331
http://dx.doi.org/10.1371/journal.pone.0158526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948848/
https://www.ncbi.nlm.nih.gov/pubmed/27428331
http://dx.doi.org/10.1371/journal.pone.0158526

Ejemplares similares